Quality of life assessment and patient acceptability of intermittent versus continuous sex hormone suppression as treatment for locally advanced or metastatic prostatic cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN51203558

Enrollment

200

Registered

2005-09-30

Start date

1997-12-31

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer: Prostate Cancer Prostate

Interventions

Intermittent vs continuous sex hormone suppression

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 200 patients recruited from Urological Oncology Clinical who have had six months androgen blockade.

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
Patient acceptance, quality of life and survival/disease progression.	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026